FGFR2 and neoplasm: FGFR2-positive diffuse type GCs classified as a small subset of patients with a poor tumor specific survival (5.29 ± 1.3 vs. 14.67 ± 1.9 months; p = 0.004) (Schrumpf et al. 2022).